formoterol (Oxis)

Subscribe to Selected New Research on formoterol

603 relevant articles (139 outcomes, 238 trials/studies) found for this Drug

Description: arformoterol is much more selective for B2-adrenoceptor than the SS-isomer and metabolic sulfation is slower; aformoterol spelling for eformoterol was only used in one citation

Also Known As:

Oxis; 3-formylamino-4-hydroxy-alpha-(N-1-methyl-2-p-methoxyphenethylaminomethyl)benzyl alcohol.hemifumarate; BD 40A; Foradil; arformoterol; eformoterol; formoterol fumarate; formoterol fumarate, ((R*,R*)-(+-))-isomer; formoterol, ((R*,R*)-(+-))-isomer; N-(2-hydroxy-5-(1-hydroxy-2-((2-(4-methoxyphenyl)-1-methylethyl)amino)ethyl)phenyl)formamide, (E)-2-butenedioate (2:1) (salt)

Relationship Network

Drug Context: Research Results

Organic Chemicals: 42

Experts

1.	Cazzola, M: 8 articles (02/2006 - 01/2001)
2.	Cazzola, Mario: 7 articles (10/2008 - 01/2003)
3.	Ekström, T: 7 articles (10/2008 - 01/2001)
4.	Matera, M G: 7 articles (02/2006 - 11/2001)
5.	Buhl, R: 6 articles (08/2007 - 03/2001)
6.	Della Cioppa, Giovanni: 6 articles (01/2006 - 04/2002)
7.	Vogelmeier, C: 5 articles (08/2007 - 03/2001)
8.	Kuna, Piotr: 5 articles (09/2006 - 02/2002)
9.	Kottakis, John: 5 articles (01/2005 - 03/2002)
10.	Pauwels, R A: 5 articles (01/2005 - 03/2000)

Related Diseases

1.	Asthma (Bronchial Asthma) 07/01/2006 - "Significant clinical data support the use of formoterol in combination with ICSs for the treatment of asthma, with studies demonstrating improved pulmonary function and symptom scores and decreased need for maintenance ICSs and short-acting beta2-adrenergic agonists (SABAs) as relief medication. " 10/01/1990 - "We conclude that formoterol in a dose of 12 micrograms via MDI confers good protection against nocturnal asthma; this was only insufficient for some patients with severe asthma, and further studies with higher dosages in these patients are clearly indicated." 10/01/2004 - "Asthma-related QOL (total score) was significantly improved with formoterol treatment compared with placebo (P < 0.015). " 05/01/2002 - "Formoterol treatment resulted in significantly greater and earlier improvements compared with the other two groups in several criteria: PEF variability (17.9 +/- 2.5; 21.9 +/- 3.2; 23.7 +/- 3.3; P < 0.001); asthma symptom score (daytime) (1.6 +/- 0.5; 1 +/- 0.5; 2.0 +/- 0,5; P < 0.05); asthma symptom score (night-time) (1.2 +/- 0.4; 2.2 +/- 0.5; 16 +/- 0.6; P < 0001); and supplement alter butalin use (1.2 +/- 0.3; 1.8 +/- 0.5; 1.7 +/- 0.5; P < 0.05). " 05/01/1991 - "This suggests that formoterol may prove to be a very useful bronchodilator for the treatment of patients with asthma who have significant airway hyperresponsiveness or nocturnal symptoms and who require inhaled beta 2-agonists at least twice daily." Order ALL the reference details at left...
2.	Chronic Obstructive Pulmonary Disease (COPD) 01/01/2008 - "There are limited clinical trial data that demonstrate that arformoterol produces significant improvement in lung function in COPD; however, many of the subjects involved had marked baseline airway reversibility. " 01/01/2009 - "These studies demonstrated that treatment with arformoterol significantly improved various lung function parameters, overall clinical status and ability to function, as well as significantly reduced COPD exacerbations and use of rescue medication. " 02/01/2008 - "CONCLUSIONS: In these trials, COPD subjects administered nebulized arformoterol demonstrated significant and sustained improvement in lung function over 12 weeks." 06/01/2008 - "CONCLUSIONS: In COPD patients not responding to the short-acting bronchodilator used in the spirometric test, formoterol promoted significant improvement in lung function at 30 min after of administration. " 05/01/2003 - "A single high dose of formoterol is as effective as the same dose administered in a cumulative manner in patients with acute exacerbation of COPD." Order ALL the reference details at left...
3.	Exercise-Induced Asthma (Asthma, Exercise Induced) 01/01/2000 - "BACKGROUND: Although formoterol, a new long-acting beta(2)-adrenergic agonist, has a rapid bronchodilating action, no studies have previously examined whether it can provide equally rapid protection against exercise-induced bronchospasm (EIB). " 10/01/2002 - "Formoterol provides long-lasting protection against exercise-induced bronchospasm." 09/01/1997 - "Sixteen children aged 8-15 yrs with exercise-induced asthma (EIA) took part in the main trial comparing the protective effect of 12 micrograms formoterol inhaled at 60 and 120 L.min-1. " 07/01/1991 - "Noncomparative studies indicate formoterol also provides effective prophylaxis of exercise-induced asthma. " 01/01/2001 - "BACKGROUND: Formoterol is a highly effective therapeutic agent in the prevention of exercise-induced bronchospasm (EIB). " Order ALL the reference details at left...
4.	Inflammation 03/01/2007 - "Formoterol as a rescue therapy is effective in relieving symptoms by relaxing airway smooth muscle but is also likely to have important inhibitory effects on mast cells, plasma exudation and neutrophilic inflammation. " 04/01/2009 - "Formoterol alone, while providing symptom relief, was no better than placebo in protecting against the allergen-induced increase in airway inflammation. " 08/01/2001 - "There was no difference in the profile of exacerbations in any groups, indicating formoterol does not mask any signs of inflammation. " 09/01/1997 - "These results suggest that the anti-inflammatory properties of formoterol in inflamed airways may contribute to the beneficial effects in the treatment of airway inflammation." 07/01/1994 - "We conclude that formoterol, acting via beta 2-adrenergic receptors, not only can reduce the amount of plasma leakage but also can reduce the number of neutrophils and eosinophils that adhere to the vascular endothelium at sites of inflammation." Order ALL the reference details at left...
5.	Dyspnea (Shortness of Breath) 10/01/2008 - "Formoterol also induced a significant change in Borg score for dyspnea caused by the 6-MWT when compared with the pre-treatment values, whereas it significantly changed dyspnea induced by 12-MWT only after the first dose. " 02/01/2007 - "CONCLUSIONS: In this trial, patients with moderate to severe COPD administered nebulized arformoterol over 12 weeks were observed to have significant and sustained improvements in airway function and dyspnea compared with placebo. " 10/01/2008 - "We assessed the effect of a 5-day treatment with formoterol 12 microg twice daily on lung function, exercise capacity and dyspnea in 22 stable COPD patients, and compared 6-MWT with 12-MWT in evaluating formoterol efficacy. " 02/01/2007 - "At week 12, TDI focal scores were significantly greater with all arformoterol doses compared with placebo (mean [95% CI]: 15 microg BID, 0.97 [0.25-1.69]; 25 microg BID, 1.08 [0.3-1.86]; 50 microg QD, 1.04 [0.32-1.771), suggesting treatment-associated improvement in dyspnea, however, the difference between salmeterol and placebo was not statistically significant (0.36 [-0.40 to 1.12]). " 04/01/2009 - "Dyspnea (mean transition dyspnea index) improved similarly for arformoterol (+2.3) and tiotropium (+1.8) and greatest with combined therapy (+3.1; p-values <0.05). " Order ALL the reference details at left...

Related Drugs and Biologics

1.	Budesonide (Pulmicort)
2.	salmeterol (Serevent)
3.	Albuterol (Salbutamol)
4.	symbicort
5.	fluticasone (Cutivate)
6.	(3,4-dihydroxyphenylamino)-2-imidazoline (DPI)
7.	tiotropium (Spiriva)
8.	Terbutaline (Brethaire)
9.	Adrenal Cortex Hormones (Corticosteroids)
10.	Ipratropium (Ipratropium Bromide)

Related Therapies and Procedures

1.	Nebulizers and Vaporizers (Inhaler)
2.	Metered Dose Inhalers (Metered Dose Inhaler)
3.	Aftercare (After-Treatment)
4.	Ambulatory Care (Outpatient Care)
5.	Respiratory Therapy (Therapy, Respiratory)

Best Treatments:
Research Summary Report
on Asthma

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 2978 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>